IMHA in Dogs: Advanced Welfare Management

An in-depth guide to immune-mediated haemolytic anaemia, one of the most serious and challenging immune-mediated diseases in dogs.

Key Facts

IMHA involves the immune system destroying red blood cells causing severe anaemia
It can be primary (idiopathic) or secondary to infection, drugs, or cancer
Affected dogs develop pale or yellow gums, rapid breathing, weakness, and collapse
Blood transfusion is often needed to stabilise severely affected dogs
Immunosuppression with prednisolone is the cornerstone of treatment
Thromboembolism is a major complication with high mortality

Welfare Considerations and Management

Welfare-centred IMHA management requires emergency stabilisation, immunosuppression, and thromboembolism prevention. Blood transfusion buys time for immunosuppression to work. Prednisolone suppresses immune destruction; additional immunosuppressants (azathioprine, mycophenolate, ciclosporin) reduce steroid requirements. Anticoagulation (heparin, aspirin, clopidogrel) reduces thromboembolism risk. Regular PCV monitoring tracks response. Relapses occur in 30-40% of cases requiring long-term monitoring.

What You Can Do

Seek emergency veterinary care immediately for dogs with sudden weakness and pale or yellow gums
Agree a monitoring plan with your vet including regular blood count checks
Understand that relapses occur — continued monitoring after treatment completion is essential
Anticoagulation management is critical to prevent fatal thromboembolism